The effect of L-thyroxine replacement therapy on ischemia-modified albümin and malondialdehyde levels in patients with overt and subclinical hypothyroidism

References

• Klein I, Danzi S. Thyroid disease and the heart. Circulation. 2007;116:1725–1735.
   PubMed Web of Science ®Google Scholar
• Mariotti S, Cambuli VM. Cardiovascular risk in elderly hypothyroid patients. Thyroid. 2007;17:1067–1073.
   PubMed Web of Science ®Google Scholar
• Biondi B, Klein I. Hypothyroidism as a risk factor for cardiovascular disease. Endocrine. 2004;24:1–13.
   PubMed Web of Science ®Google Scholar
• O’Brien T, Dinneen SF, O’Brien PC, Palumbo PJ. Hyperlipidemia in patients with primary and secondary hypothyroidism. Mayo Clin Proc. 1993;68:860–866.
   PubMed Web of Science ®Google Scholar
• Fredlund BO, Olsson SB. Long QT interval and ventricular tachycardia of “torsade de pointe” type in hypothyroidism. Acta Med Scand. 1983;213:231–235.
   PubMedGoogle Scholar
• Lekakis J, Papamichael C, Alevizaki M, et al. Flow-mediated, endothelium-dependent vasodilation is impaired in subjects with hypothyroidism, borderline hypothyroidism, and high-normal serum thyrotropin (TSH) values. Thyroid. 1997;7:411–414.
   PubMed Web of Science ®Google Scholar
• Erem C, Kavgaci H, Ersöz HO, et al. Blood coagulation and fibrinolytic activity in hypothyroidism. Int J Clin Pract. 2003;57:78–81.
   PubMed Web of Science ®Google Scholar
• Erem C, Ucuncu O, Yilmaz M, Kocak M, Nuhoglu I, Ersoz HO. Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hypothyroidism. Endocrine. 2009;35:75–80.
   PubMed Web of Science ®Google Scholar
• Erem C. Thyroid disorders and hypercoagulability. Semin Thromb Hemost. 2011;37:17–26.
   PubMed Web of Science ®Google Scholar
• Cooper DS, Biondi B. Subclinical thyroid disease. Lancet. 2012;379(9821):1142–1154.
   PubMed Web of Science ®Google Scholar
• Lioudaki E, Mavroeidi NG, Mikhailidis DP, Ganotakis ES. Subclinical hypothyroidism and vascular risk: an update. Hormones (Athens). 2013;12:495–506.
   PubMedGoogle Scholar
• Gencer B, Collet TH, Virgini V, Auer R, Rodondi N. Subclinical thyroid dysfunction and cardiovascular outcomes among prospective cohort studies. Endocr Metab Immune Disord Drug Targets. 2013;13:4–12.
   PubMed Web of Science ®Google Scholar
• Razvi S, Weaver JU, Vanderpump MP, Pearce SH. The incidence of ischemic heart disease and mortality in people with subclinical hypothyroidism: reanalysis of the Whickham Survey cohort. J Clin Endocrinol Metab. 2010;95:1734–1740.
   PubMed Web of Science ®Google Scholar
• McQuade C, Skugor M, Brennan DM, Hoar B, Stevenson C, Hoogwerf BJ. Hypothyroidism and moderate subclinical hypothyroidism are associated with increased all-cause mortality independent of coronary heart disease risk factors: A PreCIS database study. Thyroid. 2011;21:837–843.
   PubMed Web of Science ®Google Scholar
• Rodondi N, den Elzen WP, Bauer DC, et al. Thyroid studies collaboration. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA. 2010;304:1365–1374.
   PubMed Web of Science ®Google Scholar
• Tseng FY, Lin WY, Lin CC, et al. Subclinical hypothyroidism is associated with increased risk for all-cause and cardiovascular mortality in adults. J Am Coll Cardiol. 2012;60:730–737.
   PubMed Web of Science ®Google Scholar
• Parle J, Roberts L, Wilson S, et al. A randomized controlled trial of the effect of thyroxine replacement on cognitive function in community-living elderly subjects with subclinical hypothyroidism: the Birmingham Elderly Thyroid study. J Clin Endocrinol Metab. 2010;95:3623–3632.
   PubMed Web of Science ®Google Scholar
• Mishra P, Samanta L. Oxidative stress and heart failure in altered thyroid States. Sci World J. 2012;2012:741861.
   Web of Science ®Google Scholar
• Marcocci C, Leo M, Altea MA. Oxidative stress in Graves’ disease. Eur Thyroid J. 2012;1:80–87.
   PubMedGoogle Scholar
• Coria MJ, Pastrán AI, Gimenez MS. Serum oxidative stress parameters of women with hypothyroidism. Acta Biomed. 2009;80:135–139.
   PubMedGoogle Scholar
• Marchiori RC, Pereira LA, Naujorks AA, et al. Improvement of blood inflammatory marker levels in patients with hypothyroidism under levothyroxine treatment. BMC Endocr Disord. 2015;15:32.
   PubMed Web of Science ®Google Scholar
• Ates I, Yilmaz FM, Altay M, Yilmaz N, Berker D, Güler S. The relationship between oxidative stress and autoimmunity in Hashimoto’s thyroiditis. Eur J Endocrinol. 2015;173:791–799.
   PubMed Web of Science ®Google Scholar
• Torun AN, Kulaksizoglu S, Kulaksizoglu M, Pamuk BO, Isbilen E, Tutuncu NB. Serum total antioxidant status and lipid peroxidation marker malondialdehyde levels in overt and subclinical hypothyroidism. Clin Endocrinol (Oxf). 2009;70:469–474.
   PubMed Web of Science ®Google Scholar
• Haribabu A, Reddy VS, Pallavi Ch, et al. Evaluation of protein oxidation and its association with lipid peroxidation and thyrotropin levels in overt and subclinical hypothyroidism. Endocrine. 2013;44:152–157.
   PubMed Web of Science ®Google Scholar
• Konukoglu D, Ercan M, Hatemi H. Plasma viscosity in female patients with hypothyroidism: effects of oxidative stress and cholesterol. Clin Hemorheol Microcirc. 2002;27:107–113.
   PubMed Web of Science ®Google Scholar
• Kebapcilar L, Akinci B, Bayraktar F, et al. Plasma thiobarbituric acid-reactive substance levels in subclinical hypothyroidism. Med Princ Pract. 2007;16:432–436.
   PubMed Web of Science ®Google Scholar
• Dominguez-Rodriguez A, Abreu-Gonzalez P. Current role of ischemia-modified albumin in routine clinical practice. Biomarkers. 2010;15:655–662.
   PubMed Web of Science ®Google Scholar
• Sbarouni E, Georgiadou P, Voudris V. Ischemia modified albumin changes: review and clinical implications. Clin Chem Lab Med. 2011;49:177–184.
   PubMed Web of Science ®Google Scholar
• Bar-Or D, Curtis G, Rao N, Bampos N, Lau E. Characterization of the Co(2+) and Ni(2+) binding amino-acid residues of the N-terminus of human albumin. An insight into the mechanism of a new assay for myocardial ischemia. Eur J Biochem. 2001;268:42–47.
   PubMedGoogle Scholar
• Valle Gottlieb MG, da Cruz IB, Duarte MM, et al. Associations among metabolic syndrome, ischemia, inflammatory, oxidatives, and lipids biomarkers. J Clin Endocrinol Metab. 2010;95:586–591.
   PubMed Web of Science ®Google Scholar
• Reddy SV, Suchitra MM, Pradeep V, et al. Ischemia-modified albumin levels in overt and subclinical hypothyroidism. J Endocrinol Invest. 2015;38:885–890.
   PubMed Web of Science ®Google Scholar
• Ma SG, Yang LX, Bai F, Xu W, Hong B. Ischemia-modified albumin in patients with hyperthyroidism and hypothyroidism. Eur J Intern Med. 2012;23:e136–140.
   Google Scholar
• Oncel M, Kıyıcı A, Onen S. Evaluation of the relationship between ischemia-modified albumin levels and thyroid hormone levels. J Clin Lab Anal. 2015;29:427–431.
   PubMed Web of Science ®Google Scholar
• Ersoy K, Anaforoğlu İ, Algün E. Serum ischemic modified albumin levels might not be a marker of oxidative stress in patients with hypothyroidism. Endocrine. 2013;43:430–433.
   PubMed Web of Science ®Google Scholar
• Bar-Or D, Lau E, Winkler JV. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia: a preliminary report. J Emerg Med. 2000;19:311–315.
   PubMed Web of Science ®Google Scholar
• Yagi K. Assay for blood plasma or serum. Methods Enzymol. 1984;105:328–331.
   PubMed Web of Science ®Google Scholar
• Baskol G, Atmaca H, Tanriverdi F, Baskol M, Kocer D, Bayram F. Oxidative stress and enzymatic antioxidant status in patients with hypothyroidism before and after treatment. Exp Clin Endocrinol Diabetes. 2007;115:522–526.
   PubMed Web of Science ®Google Scholar
• Singh S, Sarkar PD. Lipids, oxidative stress and new emerging cardiac risk markers in subclinical hypothyroidism: before and after treatment. J Pharm Biol Sci. 2013;1:61–65.
   Google Scholar
• Guo Y, Wan SY, Zhong X, Zhong MK, Pan TR. Levothyroxine replacement therapy with vitamin E supplementation prevents the oxidative stress and apoptosis in hippocampus of hypothyroid rats. Neuro Endocrinol Lett. 2014;35:684–690.
   PubMed Web of Science ®Google Scholar
• Singh S, Dey Sarkar P. Serum lipids, tHcy, hs-CRP, MDA and PON-1 levels in SCH and overt hypothyroidism: effect of treatment. Acta Biomed. 2014;85:127–134.
   PubMedGoogle Scholar
• Cebeci E, Alibaz-Oner F, Usta M, Yurdakul S, Erguney M. Evaluation of oxidative stress, the activities of paraoxonase and arylesterase in patients with subclinical hypothyroidism. J Investig Med. 2012;60:23–28.
   PubMed Web of Science ®Google Scholar
• Piva SJ, Duarte MM, Da Cruz IB, et al. Ischemia-modified albumin as an oxidative stress biomarker in obesity. Clin Biochem. 2011;44:345–347.
   PubMed Web of Science ®Google Scholar
• Dahiya K, Verma M, Dhankhar R, Singh V, Ghalaut PS, Seth S. Alteration of ischemia modified albumin and nitric oxide levels in hypothyroidism. Clin Lab. 2014;60:969–972.
   PubMed Web of Science ®Google Scholar
• Santi A, MM Duarte, CC de Menezes, Loro VL. Association of lipids with oxidative stress biomarkers in subclinical hypothyroidism. Int J Endocrinol. 2012;2012:856359.
   PubMed Web of Science ®Google Scholar
• Ü Öztürk, Vural P, Özderya A, Karadağ B, Doğru-Abbasoğlu S, Uysal M. Oxidative stress parameters in serum and low density lipoproteins of Hashimoto’s thyroiditis patients with subclinical and overt hypothyroidism. Int Immunopharmacol. 2012;14:349–352.
   PubMed Web of Science ®Google Scholar
• Reddy VS, Gouroju S, Suchitra MM, et al. Antioxidant defense in overt and subclinical hypothyroidism. Horm Metab Res. 2013;45:754–758.
   PubMed Web of Science ®Google Scholar
• Erdamar H, Demirci H, Yaman H, et al. The effect of hypothyroidism, hyperthyroidism, and their treatment on parameters of oxidative stress and antioxidant status. Clin Chem Lab Med. 2008;46:1004–1010.
   PubMed Web of Science ®Google Scholar
• Tejovathi B, Suchitra MM, Suresh V, et al. Association of lipid peroxidation with endothelial dysfunction in patients with overt hypothyroidism. Exp Clin Endocrinol Diabetes. 2013;121:306–309.
   PubMed Web of Science ®Google Scholar
• Nanda N, Bobby Z, Hamide A. Oxidative stress and protein glycation in primary hypothyroidism. Male/female difference. Clin Exp Med. 2008;8:101–108.
   PubMed Web of Science ®Google Scholar
• Santi A, Duarte MM, Moresco RN, et al. Association between thyroid hormones, lipids and oxidative stress biomarkers in overt hypothyroidism. Clin Chem Lab Med. 2010;48:1635–1639.
   PubMed Web of Science ®Google Scholar
• Polikar R, Burger AG, Scherrer U, Nicod P. The thyroid and the heart. Circulation. 1993;87:1435–1441.
   PubMed Web of Science ®Google Scholar
• Sutken E, Inal M, Ozdemir F. Effects of vitamin E and gemfibrozil on lipid profiles, lipid peroxidation and antioxidant status in the elderly and young hyperlipidemic subjects. Saudi Med J. 2006;27:453–459.
   PubMed Web of Science ®Google Scholar
• Peppa M, Betsi G, Dimitriadis G. Lipid abnormalities and cardiometabolic risk in patients with overt and subclinical thyroid disease. J Lipids. 2011;2011:575840.
   PubMedGoogle Scholar
• Erem C, Değer O, Bostan M, et al. Plasma lipoprotein (a) concentrations in hypothyroid, euthyroid and hyperthyroid subjects. Acta Cardiol. 1999;54:77–81.
   PubMed Web of Science ®Google Scholar
• Zhu X, Cheng SY. New insights into regulation of lipid metabolism by thyroid hormone. Curr Opin Endocrinol Diabetes Obes. 2010;17:408–413.
   PubMed Web of Science ®Google Scholar
• Teixeira Pde F, Reuters VS, Ferreira MM, et al. Lipid profile in different degrees of hypothyroidism and effects of levothyroxine replacement in mild thyroid failure. Transl Res. 2008;151:224–231.
   PubMed Web of Science ®Google Scholar
• Klausen IC, Nielsen FE, Hegedüs L, Gerdes LU, Charles P, Faergeman O. Treatment of hypothyroidism reduces low-density lipoproteins but not lipoprotein(a). Metabolism. 1992;41:911–914.
   PubMed Web of Science ®Google Scholar
• Ito M, Arishima T, Kudo T, et al. Effect of levo-thyroxine replacement on non-high-density lipoprotein cholesterol in hypothyroid patients. J Clin Endocrinol Metab. 2007;92:608–611.
   PubMed Web of Science ®Google Scholar
• Tzotzas T, Krassas GE, Konstantinidis T, Bougoulia M. Changes in lipoprotein(a) levels in overt and subclinical hypothyroidism before and during treatment. Thyroid 2000;10:803–808.
   PubMed Web of Science ®Google Scholar
• Caraccio N, Ferrannini E, Monzani F. Lipoprotein profile in subclinical hypothyroidism: response to levothyroxine replacement, a randomized placebo-controlled study. J Clin Endocrinol Metab. 2002;87:1533–1538.
   PubMed Web of Science ®Google Scholar
• Erem C. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity. Clin Endocrinol. 2006;64:323–329.
   PubMed Web of Science ®Google Scholar
• Kim SK, Kim SH, Park KS, Park SW, Cho YW. Regression of the increased common carotid artery-intima media thickness in subclinical hypothyroidism after thyroid hormone replacement. Endocr J. 2009;56:753–758.
   PubMed Web of Science ®Google Scholar
• Arem R, Patsch W. Lipoprotein and apolipoprotein levels in subclinical hypothyroidism. Effect of levothyroxine therapy. Arch Intern Med. 1990;150:2097–2100.
   PubMedGoogle Scholar
• Anagnostis P, Efstathiadou ZA, Slavakis A, et al. The effect of L-thyroxine substitution on lipid profile, glucose homeostasis, inflammation and coagulation in patients with subclinical hypothyroidism. Int J Clin Pract. 2014;68:857–863.
   PubMed Web of Science ®Google Scholar